Regional differences in hemodialysis practices, treatment strategies and patient outcomes over time in Turkey: A Multicenter Observational Cohort Study in Turkish Hemodialysis Patients (20150316)

Study identification

• EU PAS number:
  EUPAS18090
• Study ID:
  18091
• Official title and acronym:
  Regional differences in hemodialysis practices, treatment strategies and patient outcomes over time in Turkey: A Multicenter Observational Cohort Study in Turkish Hemodialysis Patients (20150316)
• DARWIN EU® study:
  No
• Study countries:
  Türkiye
• Study description:
  This observational study aims to describe regional differences by focusing on real-life HD practices, treatment strategies and patient outcomes of all-cause mortality and cardiovascular morbidity in relation with treatment strategies over time in the clinical management of Turkish dialysis patients to improve standardization in HD practices and treatment strategies for patients receiving HD in Turkey.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Ankara Üniversitesi

Tıp Fakültesi Ibn-i Sina Hastanesi,Nefroloji Bilim Dalı

İstanbul Bilim Üniversitesi Tıp Fakültesi, Nefroloji Bilim Dalı İstanbul, Baskent Üniversitesi Ankara Hastanesi, Nefroloji Bilim Dalı Ankara, Hacettepe Üniversitesi Tıp Fakültesi, Nefroloji Bilim Dalı Ankara, Gazi Universitesi Tip Fakultesi, Nefroloji Anabilim Dalı Ankara, Özel Gaziosmanpaşa Yaşam Diyaliz Merkezi İstanbul, Ultra Diyaliz Merkezi İstanbul, Özel Ataşehir Diyaliz Merkezi İstanbul, Özel Merzifon Diyaliz Merkezi Amasya, Özel Keçiören Diyaliz Merkezi Ankara, Özel Nefrogrup Diyaliz Merkezi Ankara

Study timelines

Date when funding contract was signed

Planned:01/09/2016

Actual:23/09/2016

Study start date

Planned:30/11/2016

Actual:27/01/2017

Data analysis start date

Planned:30/11/2016

Date of interim report, if expected

Planned:27/07/2018

Date of final study report

Planned:05/02/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen İlaç Tic. Ltd. Şti.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable